结缔组织病相关间质性肺病：从发病机制研究到“双达标”治疗策略

doi:10.11958/20240260

天津医药 ›› 2024, Vol. 52 ›› Issue (7): 673-678.doi: 10.11958/20240260

• 专题研究·结缔组织病-间质性肺病/肺动脉高压（主编魏蔚） • 下一篇

结缔组织病相关间质性肺病：从发病机制研究到“双达标”治疗策略

李梦涛(), 王迁

中国医学科学院北京协和医院风湿免疫科，国家皮肤与免疫疾病临床医学研究中心（邮编100730）

收稿日期:2024-03-06 修回日期:2024-04-17 出版日期:2024-07-15 发布日期:2024-07-11
作者简介:李梦涛（1972），男，教授，主任医师，博士研究生/博士后导师，全国著名风湿免疫学专家。北京协和医院风湿免疫科主任，协和学者特聘教授。国家卫生健康突出贡献中青年专家，北京医学会风湿病学分会主任委员，中华医学会风湿病学分会副主任委员，中国医师协会风湿免疫科医师分会副会长兼肺血管/间质病学组组长，国家风湿病数据中心（CRDC）及中国风湿免疫病医联体联盟（CRCA）秘书长，国家皮肤与免疫疾病临床医学研究中心（NCRC-DID）办公室主任，风湿免疫病学教育部重点实验室主任。《Rheumatology and Immunology Research（RIR）》副主编。系统性红斑狼疮研究国家十四五重点研发计划项目首席专家，十三五重点研发计划、首都协同创新重点项目及国自然课题负责人。E-mail：mengtao.li@cstar.org.cn

Connective tissue disease-associated interstitial lung disease: from pathogenesis to "dual-target" treatment strategies

LI Mengtao(), WANG Qian

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing 100730, China

Received:2024-03-06 Revised:2024-04-17 Published:2024-07-15 Online:2024-07-11

李梦涛, 王迁. 结缔组织病相关间质性肺病：从发病机制研究到“双达标”治疗策略[J]. 天津医药, 2024, 52(7): 673-678.

LI Mengtao, WANG Qian. Connective tissue disease-associated interstitial lung disease: from pathogenesis to "dual-target" treatment strategies[J]. Tianjin Medical Journal, 2024, 52(7): 673-678.

摘要/Abstract

摘要：

结缔组织病（CTD）是一类多器官系统受累的异质性疾病，间质性肺病（ILD）是多种CTD的严重并发症。不同CTD-ILD在发病机制、临床表现、治疗等方面存在较大异质性。基于遗传学、病理生理与免疫学、蛋白质组学、微生物组学进行相关基础及临床研究来探究CTD-ILD发病机制并提出“双达标”治疗策略。影像学技术及血清生物标志物研究的进展同时助力“双达标”治疗策略的实施，早期控制CTD活动与肺部炎症、延缓肺纤维化有利于改善CTD-ILD患者生存期与生活质量。

关键词: 结缔组织疾病, 肺疾病，间质性, 诊断, 治疗, 发病机制

Abstract:

Connective tissue diseases (CTD) are a spectrum of heterogeneous diseases with multiple organ involvements. Interstitial lung diseases (ILD) are serious complications of CTD. There is great heterogeneity in pathogenesis, clinical manifestations, and treatment of different CTD-ILD. Previous basic and clinical studies have explored the pathogenesis of CTD-ILD, and the "dual-target" treatment strategy has therefore emerged. The implementation of the "dual-target" treatment strategy helps to control CTD activity and lung inflammation in the early stage, prevent the progression of pulmonary fibrosis, and thus improve patient survival and quality of life.

Key words: connective tissue diseases, lung diseases, interstitial, diagnosis, therapy, pathogenesis

中图分类号:

R593.2

参考文献 47

[1]	MIRA-AVENDANO I, ABRIL A, BURGER C D, et al. Interstitial lung disease and other pulmonary manifestations in connective tissue diseases[J]. Mayo Clin Proc, 2019, 94(2):309-325. doi:10.1016/j.mayocp.2018.09.002.
[2]	MATHAI S C, DANOFF S K. Management of interstitial lung disease associated with connective tissue disease[J]. BMJ, 2016,352:h6819. doi:10.1136/bmj.h6819.
[3]	JOY G M, ARBIV O A, WONG C K, et al. Prevalence,imaging patterns and risk factors of interstitial lung disease in connective tissue disease:a systematic review and meta-analysis[J]. Eur Respir Rev, 2023, 32(167):220210. doi:10.1183/16000617.0210-2022.
[4]	中国医师协会风湿免疫科医师分会风湿病相关肺血管/间质病学组, 国家风湿病数据中心. 2018中国结缔组织病相关间质性肺病诊断和治疗专家共识[J]. 中华内科杂志, 2018, 57(8):558-565.
	Rheumatology Related Pulmonary Vascular/Interstitial Epidemiology Group, Rheumatology and Immunology Division,Chinese Medical Doctor Association,National Rheumatology Data Center. 2018 Chinese expert-based consensus statement regarding the diagnosis and treatment of interstitial lung disease associated with connective tissue diseases[J]. Chin J Intern Med, 2018, 57(8):558-565. doi:10.3760/cma.j.issn.0578-1426.2018.08.005.
[5]	SHAO T, SHI X, YANG S, et al. Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations[J]. Front Immunol, 2021,12:684699. doi:10.3389/fimmu.2021.684699.
[6]	CERRO CHIANG G, PARIMON T. Understanding interstitial lung diseases associated with connective tissue disease(CTD-ILD):genetics,cellular pathophysiology,and biologic drivers[J]. Int J Mol Sci, 2023, 24(3):2405. doi:10.3390/ijms24032405.
[7]	SPAGNOLO P, DISTLER O, RYERSON C J, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)[J]. Ann Rheum Dis, 2021, 80(2):143-150. doi:10.1136/annrheumdis-2020-217230.
[8]	TSENG C C, SUNG Y W, CHEN K Y, et al. The Role of Macrophages in connective tissue disease-associated interstitial lung disease: focusing on molecular mechanisms and potential treatment strategies[J]. Int J Mol Sci, 2023, 24(15):11995. doi:10.3390/ijms241511995.
[9]	WU Y, LI Y, LUO Y, et al. Proteomics: potential techniques for discovering the pathogenesis of connective tissue diseases-interstitial lung disease[J]. Front Immunol, 2023,14:1146904. doi:10.3389/fimmu.2023.1146904.
[10]	SCHER J U, JOSHUA V, ARTACHO A, et al. The lung microbiota in early rheumatoid arthritis and autoimmunity[J]. Microbiome, 2016, 4(1):60. doi:10.1186/s40168-016-0206-x.
[11]	ANDRÉASSON K, LEE S M, LAGISHETTY V, et al. Disease features and gastrointestinal microbial composition in patients with systemic sclerosis from two independent cohorts[J]. ACR Open Rheumatol, 2022, 4(5):417-425. doi:10.1002/acr2.11387.
[12]	VERES-SZÉKELY A, SZÁSZ C, PAP D, et al. Zonulin as a potential therapeutic target in microbiota-gut-brain axis disorders: encouraging results and emerging questions[J]. Int J Mol Sci, 2023, 24(8):7548. doi:10.3390/ijms24087548.
[13]	DRAKOPANAGIOTAKIS F, STAVROPOULOU E, TSIGALOU C, et al. The role of the microbiome in connective-tissue-associated interstitial lung disease and pulmonary vasculitis[J]. Biomedicines, 2022, 10(12):3195. doi:10.3390/biomedicines10123195.
[14]	JEON H, NAM B D, YOON C H, et al. Radiologic approach and progressive exploration of connective tissue disease-related interstitial lung disease: meeting the curiosity of rheumatologists[J]. J Rheum Dis, 2024, 31(1):3-14. doi:10.4078/jrd.2023.0042.
[15]	PUGASHETTI J V, KHANNA D, KAZEROONI E A, et al. Clinically relevant biomarkers in connective tissue disease-associated interstitial lung disease[J]. Immunol Allergy Clin North Am, 2023, 43(2):411-433. doi:10.1016/j.iac.2023.01.012.
[16]	ANTHIMOPOULOS M, CHRISTODOULIDIS S, EBNER L, et al. Lung pattern classification for interstitial lung diseases using a deep convolutional neural network[J]. IEEE Trans Med Imaging, 2016, 35(5):1207-1216. doi:10.1109/TMI.2016.2535865.
[17]	JACOB J, HIRANI N, VAN MOORSEL C, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease[J]. Eur Respir J, 2019, 53(1): 1800869. doi:10.1183/13993003.00869-2018.
[18]	WANG Y, GARGANI L, BARSKOVA T, et al. Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease:a literature review[J]. Arthritis Res Ther, 2017, 19(1):206. doi:10.1186/s13075-017-1409-7.
[19]	WANG Y, CHEN S, ZHENG S, et al. The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease:review of the literature,proposal for a preliminary algorithm,and clinical application to cases[J]. Arthritis Res Ther, 2021, 23(1):212. doi:10.1186/s13075-021-02586-9.
[20]	BROENS B, DUITMAN J W, ZWEZERIJNEN G, et al. Novel tracers for molecular imaging of interstitial lung disease:A state of the art review[J]. Autoimmun Rev, 2022, 21(12):103202. doi:10.1016/j.autrev.2022.103202.
[21]	MARIE I, JOSSE S, DECAUX O, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome[J]. Autoimmun Rev, 2012, 11(10):739-745. doi:10.1016/j.autrev.2012.01.006.
[22]	MIĄDLIKOWSKA E, RZEPKA-WRONA P, MIłKOWSKA-DYMANOWSKA J, et al. Review:serum biomarkers of lung fibrosis in interstitial pneumonia with autoimmune features-what do we already know?[J]. J Clin Med, 2021, 11(1):89. doi:10.3390/jcm11010079.
[23]	TOMASSETTI S, COLBY T V, WELLS A U, et al. Bronchoalveolar lavage and lung biopsy in connective tissue diseases,to do or not to do?[J]. Ther Adv Musculoskelet Dis, 2021,13:1759720X211059605. doi:10.1177/1759720X211059605.
[24]	JAEGER V K, WIRZ E G, ALLANORE Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal eustar study[J]. PLoS One, 2016, 11(10):e0163894. doi:10.1371/journal.pone.0163894.
[25]	ZAMORA-LEGOFF J A, KRAUSE M L, CROWSON C S, et al. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease[J]. Arthritis Rheumatol, 2017, 69(3):542-549. doi:10.1002/art.39971.
[26]	MARIE I, HATRON P Y, DOMINIQUE S, et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients[J]. Arthritis Rheum, 2011, 63(11):3439-3447. doi:10.1002/art.30513.
[27]	PARAMBIL J G, MYERS J L, LINDELL R M, et al. Interstitial lung disease in primary Sjögren syndrome[J]. Chest, 2006, 130(5):1489-1495. doi:10.1378/chest.130.5.1489.
[28]	AHMED S, HANDA R. Management of connective tissue disease-related interstitial lung disease[J]. Curr Pulmonol Rep, 2022, 11(3):86-98. doi:10.1007/s13665-022-00290-w.
[29]	WILSON T M, SOLOMON J J, DEMORUELLE M K. Treatment approach to connective tissue disease-associated interstitial lung disease[J]. Curr Opin Pharmacol, 2022,65:102245. doi:10.1016/j.coph.2022.102245.
[30]	American College of Rheumatology Empowering Rheumatology Professionals. 2023 American College of Rheumatology(ACR)guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic disease[EB/OL]. (2023-08-23)[2024-03-06]. https://rheumatology.org/interstitial-lung-disease-guideline#2023-ild-guideline.
[31]	BARNES H, HOLLAND A E, WESTALL G P, et al. Cyclophosphamide for connective tissue disease-associated interstitial lung disease[J]. Cochrane Database Syst Rev, 2018, 1(1):CD010908. doi:10.1002/14651858.CD010908.pub2.
[32]	BARBA T, FORT R, COTTIN V, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease:A systematic review and meta-analysis[J]. Autoimmun Rev, 2019, 18(2):113-122. doi:10.1016/j.autrev.2018.07.013.
[33]	MATSON S M, BAQIR M, MOUA T, et al. Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world,multisite study of the impact of immunosuppression on pulmonary function trajectory[J]. Chest, 2023, 163(4):861-869. doi:10.1016/j.chest.2022.11.035.
[34]	MAHER T M, TUDOR V A, SAUNDERS P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL):a double-blind,double-dummy,randomised,controlled,phase 2b trial[J]. Lancet Respir Med, 2023, 11(1):45-54. doi:10.1016/S2213-2600(22)00359-9.
[35]	ASSASSI S, VOLKMANN E R, ZHENG W J, et al. Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease[J]. Ann Rheum Dis, 2022, 81(6):854-860. doi:10.1136/annrheumdis-2021-221313.
[36]	KARAKONTAKI F V, PANSELINAS E S, POLYCHRONOPOULOS V S, et al. Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development[J]. Autoimmun Rev, 2021, 20(2):102742. doi:10.1016/j.autrev.2020.102742.
[37]	HUAPAYA J A, SILHAN L, PINAL-FERNANDEZ I, et al. Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease[J]. Chest, 2019, 156(5):896-906. doi:10.1016/j.chest.2019.05.023.
[38]	KHANNA D, LIN C, FURST D E, et al. Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial[J]. Am J Respir Crit Care Med, 2022, 205(6):674-684. doi:10.1164/rccm.202103-0714OC.
[39]	ROOFEH D, LIN C, GOLDIN J, et al. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease[J]. Arthritis Rheumatol, 2021, 73(7):1301-1310. doi:10.1002/art.41668.
[40]	VICENTE-RABANEDA E F, ATIENZA-MATEO B, BLANCO R, et al. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis:A systematic literature review[J]. Autoimmun Rev, 2021, 20(6):102830. doi:10.1016/j.autrev.2021.102830.
[41]	BELLAN M, PATRUCCO F, BARONE-ADESI F, et al. Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases:A systematic review[J]. Autoimmun Rev, 2020, 19(2):102453. doi:10.1016/j.autrev.2019.102453.
[42]	KHANNA D, LESCOAT A, ROOFEH D, et al. Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice[J]. Arthritis Rheumatol, 2022, 74(1):13-27. doi:10.1002/art.41933.
[43]	HIGHLAND K B, DISTLER O, KUWANA M, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate:a subgroup analysis of the SENSCIS trial[J]. Lancet Respir Med, 2021, 9(1):96-106. doi:10.1016/S2213-2600(20)30330-1.
[44]	SEIBOLD J R, MAHER T M, HIGHLAND K B, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease:data from the SENSCIS trial[J]. Ann Rheum Dis, 2020, 79(11):1478-1484. doi:10.1136/annrheumdis-2020-217331.
[45]	DISTLER O, HIGHLAND K B, GAHLEMANN M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease[J]. N Engl J Med, 2019, 380(26):2518-2528. doi:10.1056/NEJMoa1903076.
[46]	PECHER A C, HENSEN L, KLEIN R, et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome[J]. JAMA, 2023, 329(24):2154-2162. doi:10.1001/jama.2023.8753.
[47]	PERELAS A, SILVER R M, ARROSSI A V, et al. Systemic sclerosis-associated interstitial lung disease[J]. Lancet Respir Med, 2020, 8(3):304-320. doi:10.1016/S2213-2600(19)30480-1.

结缔组织病相关间质性肺病：从发病机制研究到“双达标”治疗策略

Connective tissue disease-associated interstitial lung disease: from pathogenesis to "dual-target" treatment strategies

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 47

相关文章 15

编辑推荐

Metrics

本文评价

[1]	靳芳, 冯靖. 细胞学涂片在肺结节术中的快速病理诊断价值[J]. 天津医药, 2024, 52(9): 946-949.
[2]	杨敏, 潘艳莎, 张长玲, 陈红英, 郭渠莲, 刘文君. 儿童急性淋巴细胞白血病基线数据及早期治疗反应与预后的相关性[J]. 天津医药, 2024, 52(9): 954-958.
[3]	王磊, 孟坤, 王兵. 支气管肺炎患儿反复喘息的影响因素分析及预测模型构建[J]. 天津医药, 2024, 52(8): 850-853.
[4]	金彩凤, 吴玮, 吴轲. B族链球菌感染及阴道微生态变化与不良妊娠结局的关系[J]. 天津医药, 2024, 52(8): 858-861.
[5]	张国华, 张令令, 高兰, 罗俊丽, 申雅文, 刘磊, 王玉华. 结缔组织病相关间质性肺病合并肺癌16例临床分析[J]. 天津医药, 2024, 52(7): 687-690.
[6]	武才鑫, 闫彦, 邓瑗琳, 杜雅敏, 杨振文, 潘晴, 杨帆. 心脏磁共振评估结缔组织病伴重度肺动脉高压的价值[J]. 天津医药, 2024, 52(7): 691-694.
[7]	尹韦玉, 廖红丽, 刘媛. SS相关抗体在特发性炎症性肌病及其相关间质性肺炎中的临床意义[J]. 天津医药, 2024, 52(7): 695-700.
[8]	刘智超, 李霄鹤, 周红刚, 张娜. 特发性炎性肌病相关间质性肺疾病动物模型概述[J]. 天津医药, 2024, 52(7): 709-713.
[9]	陈芷彦, 伍秋苑, 邓裕华, 周丹. 类器官技术在乳腺癌研究中的现状及应用[J]. 天津医药, 2024, 52(6): 668-672.
[10]	王灵, 龙登炎. 重症监护病房获得性衰弱风险预测模型的构建[J]. 天津医药, 2024, 52(5): 486-489.
[11]	邵红霞, 吴涓涓, 于洪志, 吴琦, 武俊平. 血行播散性肺结核合并颅内结核的临床特点[J]. 天津医药, 2024, 52(5): 495-498.
[12]	薛文平, 秦巍, 刘婷婷, 张爱文, 史菲. 老年急性冠脉综合征患者PCI术前血清miR-34a、miR-182水平与术后对比剂肾病发生的相关性[J]. 天津医药, 2024, 52(4): 422-426.
[13]	王鑫瑶, 杨惠, 李冰冰. 间充质干细胞在子宫内膜异位症中的研究进展[J]. 天津医药, 2024, 52(2): 215-219.
[14]	付秀娟, 卢祖能. 糖尿病合并慢性炎性脱髓鞘性多发性神经根神经病研究进展[J]. 天津医药, 2024, 52(2): 220-224.
[15]	陆艺蓓, 金冬霞, 宋振春, 马昊原, 李彦, 郝天旭, 李曦铭. 新型柔性贴片式心电仪的临床应用[J]. 天津医药, 2024, 52(10): 1095-1099.